M Wirth

Summary

Country: Germany

Publications

  1. doi request reprint A Multicenter Phase 1 Study of EMD 525797 (DI17E6), a Novel Humanized Monoclonal Antibody Targeting αv Integrins, in Progressive Castration-resistant Prostate Cancer with Bone Metastases After Chemotherapy
    Manfred Wirth
    Department of Urology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany Electronic address
    Eur Urol 65:897-904. 2014
  2. pmc The application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trial
    Maximilian Burger
    Department of Urology, Caritas St, Josef Medical Centre, University of Regensburg, Regensburg, Germany
    J Transl Med 8:54. 2010
  3. doi request reprint Adjuvant hormonal treatment - the bicalutamide early prostate cancer program
    Manfred P Wirth
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    Front Radiat Ther Oncol 41:39-48. 2008
  4. ncbi request reprint Antiandrogens in the treatment of prostate cancer
    Manfred P Wirth
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Fetscherstrasse 74, D 01307 Dresden, Germany
    Eur Urol 51:306-13; discussion 314. 2007
  5. ncbi request reprint [Treatment of locally advanced prostate cancer]
    M P Wirth
    Klinik und Poliklinik fur Urologie, Universitatsklinikum Carl Gustav Carus, Technische Universitat, Dresden
    Urologe A 44:1295-302. 2005
  6. ncbi request reprint Optimal treatment of locally advanced prostate cancer
    Manfred P Wirth
    Department of Urology, University Hospital, Carl Gustav Carus, Technical University of Dresden, Fetscherstrasse 74, 01307 Dresden, Germany
    World J Urol 25:169-76. 2007
  7. doi request reprint [Prostate cancer. Current and practice-relevant news from urology in 2011]
    M Wirth
    Universitatsklinikum Dresden, Fetscherstrasse 74, Dresden, Germany
    Urologe A 50:173-5. 2011
  8. ncbi request reprint Hormone-refractory prostate cancer: what have we learned?
    Manfred P Wirth
    Department of Urology, Technical University Dresden, Dresden, Germany
    BJU Int 100:56-9. 2007
  9. ncbi request reprint Lymph node disease after radical prostatectomy
    M P Wirth
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    Minerva Urol Nefrol 59:53-7. 2007
  10. ncbi request reprint [The significance of comorbidity and age in radical prostatectomy]
    M Wirth
    Klinik und Poliklinik fur Urologie, Universitätsklinikum Carl Gustav Carus der technischen Universität Dresden
    Urologe A 43:935-41. 2004

Detail Information

Publications88

  1. doi request reprint A Multicenter Phase 1 Study of EMD 525797 (DI17E6), a Novel Humanized Monoclonal Antibody Targeting αv Integrins, in Progressive Castration-resistant Prostate Cancer with Bone Metastases After Chemotherapy
    Manfred Wirth
    Department of Urology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany Electronic address
    Eur Urol 65:897-904. 2014
    ..EMD 525797 (DI17E6) is a deimmunized, humanized monoclonal immunoglobulin G2 antibody against the αv subunit of human integrins. Blocking αv integrins may be an effective strategy for inhibiting prostate cancer (PCa) metastasis...
  2. pmc The application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trial
    Maximilian Burger
    Department of Urology, Caritas St, Josef Medical Centre, University of Regensburg, Regensburg, Germany
    J Transl Med 8:54. 2010
    ..The present trial compared autologous intravesical macrophage cell therapy (BEXIDEM) to BCG in patients after transurethral resection (TURB) of BC...
  3. doi request reprint Adjuvant hormonal treatment - the bicalutamide early prostate cancer program
    Manfred P Wirth
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    Front Radiat Ther Oncol 41:39-48. 2008
    ..Altogether, there is no indication for treatment with bicalutamide in patients with localized disease...
  4. ncbi request reprint Antiandrogens in the treatment of prostate cancer
    Manfred P Wirth
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Fetscherstrasse 74, D 01307 Dresden, Germany
    Eur Urol 51:306-13; discussion 314. 2007
    ..To give an overview on the contemporary role of antiandrogens in prostate cancer treatment...
  5. ncbi request reprint [Treatment of locally advanced prostate cancer]
    M P Wirth
    Klinik und Poliklinik fur Urologie, Universitatsklinikum Carl Gustav Carus, Technische Universitat, Dresden
    Urologe A 44:1295-302. 2005
    ..If in case of severe comorbidity or advanced age primary hormonal treatment is chosen, early vs deferred treatment seems to prolong survival marginally...
  6. ncbi request reprint Optimal treatment of locally advanced prostate cancer
    Manfred P Wirth
    Department of Urology, University Hospital, Carl Gustav Carus, Technical University of Dresden, Fetscherstrasse 74, 01307 Dresden, Germany
    World J Urol 25:169-76. 2007
    ..Adjuvant hormonal treatment may improve outcome in this setting. When no curative treatment is chosen, early hormonal treatment seems to provide modest benefit compared with deferred therapy...
  7. doi request reprint [Prostate cancer. Current and practice-relevant news from urology in 2011]
    M Wirth
    Universitatsklinikum Dresden, Fetscherstrasse 74, Dresden, Germany
    Urologe A 50:173-5. 2011
    ..For metastasized prostate cancer new immunotherapeutic, chemotherapeutic and hormonal options are now available or will soon be approved...
  8. ncbi request reprint Hormone-refractory prostate cancer: what have we learned?
    Manfred P Wirth
    Department of Urology, Technical University Dresden, Dresden, Germany
    BJU Int 100:56-9. 2007
  9. ncbi request reprint Lymph node disease after radical prostatectomy
    M P Wirth
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    Minerva Urol Nefrol 59:53-7. 2007
    ..Overall, there is a need to enroll patients with lymph node involvement at radical prostatectomy onto clinical studies to improve the body of knowledge on optimal management in these cases...
  10. ncbi request reprint [The significance of comorbidity and age in radical prostatectomy]
    M Wirth
    Klinik und Poliklinik fur Urologie, Universitätsklinikum Carl Gustav Carus der technischen Universität Dresden
    Urologe A 43:935-41. 2004
    ..The identification of prognostically relevant single conditions and the development of a "radical prostatectomy-specific" comorbidity classification might improve the stratification of candidates for radical prostatectomy in the future...
  11. ncbi request reprint Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years
    Manfred P Wirth
    Department of Urology, Technical University of Dresden, Dresden, Germany
    J Urol 172:1865-70. 2004
    ..We evaluated the efficacy and tolerability of 150 mg bicalutamide daily given in addition to standard care, in patients with localized or locally advanced prostate cancer...
  12. ncbi request reprint Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up
    M Wirth
    Department of Urology, Technical University of Dresden, Dresden, Germany
    Prostate Cancer Prostatic Dis 10:87-93. 2007
    ..66; 95% confidence interval 0.55, 0.79; P<0.001). In localized disease, a significant difference in objective PFS was not found. There was no significant difference in overall survival...
  13. ncbi request reprint Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression
    M Wirth
    Department of Urology, Technical University of Dresden, Dresden, Germany
    Urology 58:146-51. 2001
    ..Longer follow-up is underway to assess any benefit in overall survival...
  14. doi request reprint [Value of lymphadenectomy for limited nodal recurrence of prostate cancer after local therapy with curative intent]
    I Wolff
    Klinik und Poliklinik fur Urologie, Universitatsklinikum Carl Gustav Carus, Technische Universitat Dresden, Fetscherstr 74, 01307, Dresden, Deutschland
    Urologe A 47:1436-40. 2008
    ..The available data on oncological outcomes of this procedure are insufficient. Therefore, lymphadenectomy for nodal recurrence of prostate cancer remains an unproven approach...
  15. ncbi request reprint Adjuvant hormonal treatment for prostate cancer: the bicalutamide early prostate cancer program
    Manfred P Wirth
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    Oncology 65:1-4. 2003
    ..58, 95% confidence interval 0.51-0.66, p < 0.0001). However, further maturation of data is needed to see whether this difference will lead to a survival advantage...
  16. ncbi request reprint Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme
    M Wirth
    Technical University of Dresden Medical School, Dresden, Germany
    Prostate Cancer Prostatic Dis 8:194-200. 2005
    ..746). In the context of the whole EPC programme, long-term bicalutamide is not appropriate for localised disease, yet provides advantages in delaying disease progression in patients with locally advanced prostate cancer...
  17. doi request reprint [Pelvic lymphadenectomy and radical prostatectomy. Recommendations of the German S3 guideline]
    M O Grimm
    Klinik und Poliklinik fur Urologie, Universitatsklinikum Carl Gustav Carus, Technische Universitat Dresden, Fetscherstrasse 74, 01307 Dresden
    Urologe A 49:206-10. 2010
    ..Radical prostatectomy has to be performed under the supervision of an experienced surgeon. This includes the number of 50 prostatectomies per year and institution, 25 prostatectomies per surgeon, and an appropriate training program...
  18. ncbi request reprint Delaying/reducing the risk of clinical tumour progression after primary curative procedures
    M Wirth
    Department of Urology, Technical University of Dresden, Germany
    Eur Urol 40:17-23. 2001
    ..The programme is ongoing, and survival data are awaited...
  19. ncbi request reprint Quantification of C13orf19/P38IP mRNA expression by quantitative real-time PCR in patients with urological malignancies
    Uta Schmidt
    Department of Urology, Technical University of Dresden, Fetscherstr 74, D 01307 Dresden, Germany
    Cancer Lett 225:253-60. 2005
    ..5-fold upregulation was observed in samples from 17 patients (28%). In contrast, C13orf19 mRNA alterations in expression seemed to be random events in kidney cancers...
  20. ncbi request reprint siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth
    Shuangli Ning
    Department of Urology, Technical University Dresden, Fetscherstrasse 74, D 01307 Dresden, Germany
    Int J Oncol 25:1065-71. 2004
    ..In summary, the results suggest that the anti-survivin siRNA treatment might represent a suitable therapeutic approach to selectively inhibit growth of BCa cells in addition to commonly applied therapy schemes...
  21. ncbi request reprint D-PCa-2: a novel transcript highly overexpressed in human prostate and prostate cancer
    Bernd Weigle
    Institute of Immunology, Medical Faculty, Technical University Dresden, Dresden, Germany
    Int J Cancer 109:882-92. 2004
    ..These results validate D-PCa-2 as a transcript with high tissue specificity and with a potential application in the diagnosis of PCa...
  22. doi request reprint [Molecular genetic markers for prostate cancer. Evidence in fine needle biopsies for improved confirmation of the diagnosis]
    S Schneider
    Klinik für Urologie, Technische Universitat, Dresden, Deutschland
    Urologe A 47:1208-11. 2008
    ..Furthermore, an extension of this approach to PCa prognosis and the transfer to urine samples appear very promising...
  23. ncbi request reprint Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and Cisplatin
    Sabine Krause
    Institutes of Biochemistry, Technical University Dresden, Dresden, Germany
    J Urol 174:328-31. 2005
    ..We investigated the possibility of sensitizing transitional bladder cancer cell lines to CT by pretreatment with VEGF antisense (AS) oligodeoxynucleotides (AS-ODNs)...
  24. ncbi request reprint Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy
    Michael Froehner
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    Urology 62:698-701. 2003
    ..The ASA classification is a widely accepted way to evaluate perioperative risk. At present, the Charlson score is probably the most frequently used comorbidity measure to predict long-term survival after radical prostatectomy...
  25. ncbi request reprint Value of endocrine therapy for early and locally advanced prostate cancer
    Manfred P Wirth
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Germany
    Drugs Aging 20:115-24. 2003
    ..Several large studies are under way to investigate the role of adjuvant treatment in the field of early prostate cancer...
  26. ncbi request reprint Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells
    Kai Kraemer
    Department of Urology, Technical University Dresden, D 01307, Dresden, Germany
    Clin Cancer Res 9:3794-800. 2003
    ..The aim of this study was to investigate whether hTERT inhibition by antisense oligodeoxynucleotides (AS-ODN) can act as an efficient strategy to specifically impair the growth of bladder cancer (BCa) cells in vitro...
  27. ncbi request reprint Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer
    Manfred P Wirth
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Fetscherstrasse 74, D 01307 Dresden, Germany
    Eur Urol 45:267-70; discussion 270. 2004
    ..To assess the efficacy and the tolerability of flutamide as adjuvant treatment after radical prostatectomy for locally advanced, lymph node-negative prostate cancer...
  28. ncbi request reprint Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR
    Susanne Fuessel
    Department of Urology, Technical University Dresden, Fetscherstrasse 74, D 01307 Dresden, Germany
    Int J Oncol 23:221-8. 2003
    ..According to our data, the novel marker trp-p8 seems to represent a highly prostate-specific and PCa-associated gene qualifying it as a potential target for specific therapies...
  29. ncbi request reprint Perspectives in adjuvant treatment of prostate cancer
    Manfred P Wirth
    Department of Urology, University Clinics Carl Gustav Carus, Technical University of Dresden, Germany wirth msrcs urz tu dresdan de
    Urol Int 68:1-5. 2002
  30. ncbi request reprint Quantitative multi-gene expression profiling of primary prostate cancer
    Uta Schmidt
    Department of Urology, Technical University of Dresden, Germany
    Prostate 66:1521-34. 2006
    ..This study describes the evaluation of the expression patterns of prostate-related transcripts in 106 matched prostate tissues from prostatectomies as predictors for prostate cancer (PCa)...
  31. ncbi request reprint D-GPCR: a novel putative G protein-coupled receptor overexpressed in prostate cancer and prostate
    Bernd Weigle
    Institute of Immunology, Medical Faculty, Technical University of Dresden, Germany
    Biochem Biophys Res Commun 322:239-49. 2004
    ..These data provide the basis for future studies evaluating the diagnostic potential of D-GPCR and its utility as a novel target in immunotherapy of prostate cancer...
  32. ncbi request reprint The role of toll-like receptors in the immune-adrenal crosstalk
    S R Bornstein
    Department of Anesthesiology, Heinrich Heine University, Dusseldorf, Germany
    Ann N Y Acad Sci 1088:307-18. 2006
    ..In conclusion, TLRs play a crucial role in the immune-adrenal crosstalk. This close functional relationship needs to be considered in the treatment of inflammatory diseases requiring an intact adrenal stress response...
  33. doi request reprint Detailed analysis of Charlson comorbidity score as predictor of mortality after radical prostatectomy
    Michael Froehner
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    Urology 72:1252-7. 2008
    ..To investigate the prognostic significance of the individual conditions contributing to the Charlson comorbidity score in patients selected for radical prostatectomy...
  34. doi request reprint Derivatives of prostate-specific antigen as predictors of incidental prostate cancer
    Michael Froehner
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    BJU Int 104:25-8. 2009
    ..5-10 ng/ml...
  35. ncbi request reprint Successful chemotherapy for advanced nonseminomatous germ-cell tumor in a patient undergoing chronic hemodialysis
    Michael Froehner
    Department of Urology, University Hospital, Technical University of Dresden, Dresden, Germany
    J Clin Oncol 25:1282-4. 2007
  36. doi request reprint Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient
    Daniela Wuttig
    Department of Urology, Dresden University of Technology, Dresden, Germany
    Int J Cancer 125:474-82. 2009
    ..To what extent the identified molecular factors contribute to the development of these characteristics of metastatic spread needs to be analyzed in further studies...
  37. ncbi request reprint Changing comorbidity classification patterns at radical prostatectomy during a 10-year period
    Michael Froehner
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    Urol Oncol 25:26-31. 2007
    ..To investigate the consistency of several comorbidity classifications and concomitant diseases at radical prostatectomy (RP) during a 10-year period...
  38. ncbi request reprint Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma
    Oliver W Hakenberg
    Department of Urology, University Hospital Carl Gustav Carus, Technical University, Dresden, Germany
    BJU Int 98:1225-7. 2006
    ....
  39. doi request reprint Second cancers as competing causes of death after radical prostatectomy
    Michael Froehner
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    J Urol 182:967-70. 2009
    ..We analyzed the risk of dying of a second cancer after radical prostatectomy for clinically localized prostate cancer...
  40. ncbi request reprint Treatment of locally advanced prostate cancer--the case for radical prostatectomy
    Oliver W Hakenberg
    Klinik und Poliklinik fur Urologie, Universitätsklinikum Carl Gustav Carus der technischen Universität Dresden, Dresden, Germany
    Urol Int 77:193-9. 2006
    ..If, in case of advanced age and/or significant comorbidity, primary hormonal treatment is chosen, early hormonal deprivation therapy seems to offer marginal benefits in survival compared to delayed treatment...
  41. ncbi request reprint Magnetic resonance imaging of bone metastases in patients with nonseminomatous germ cell tumors
    Michael Froehner
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    Urol Oncol 25:201-6. 2007
    ..To investigate the role of magnetic resonance imaging (MRI) of bone metastases in nonseminomatous germ cell tumors...
  42. ncbi request reprint Molecular therapy in urologic oncology
    Michael Froehner
    Department of Urology, University Hospital, Technical University of Dresden, Dresden, Germany
    Urol Int 79:1-7. 2007
    ..The great theoretical potential and the multitude of possible targets and drug combinations, however, support further research into this exciting field of medical treatment of urologic malignancies...
  43. doi request reprint Treatment of metastatic renal cell cancer with sunitinib during chronic hemodialysis
    Stefan Zastrow
    Department of Urology, University Hospital Carl Gustav Carus, Dresden, Germany
    Urology 73:868-70. 2009
    ..To report on 2 cases of metastatic renal cell cancer treated with sunitinib during chronic hemodialysis...
  44. doi request reprint Anticholinergic effects of cis- and trans-isomers of two metabolites of propiverine
    Stefan Propping
    Department of Urology, University Hospital Carl Gustav Carus, Dresden University of Technology, Fetscherstrasse 74, 01307 Dresden, Germany
    Naunyn Schmiedebergs Arch Pharmacol 381:329-38. 2010
    ..However, at higher concentration ranges, all four compounds seem to have additional effects on Ca(2+) influx...
  45. doi request reprint Expression of the Forkhead transcription factor FOXP1 is associated with tumor grade and Ki67 expression in clear cell renal cell carcinoma
    Marieta I Toma
    Institute of Pathology, Medicine University Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    Cancer Invest 29:123-9. 2011
    ..05). The overall survival and the disease-specific survival correlated negatively with the Ki67 status (p < .05). FOXP1 expression negatively correlated with Ki67 expression in clear cell renal cell carcinomas (p = .036)...
  46. pmc Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array
    Marieta I Toma
    Institute for Pathology, University of Technology Dresden, D 01307 Dresden, Germany
    Neoplasia 10:634-42. 2008
    ..Genome-wide SNP array analysis not only confirmed previously described large chromosomal aberrations but also detected novel microdeletions in genes potentially involved in tumor genesis of cc-RCC...
  47. ncbi request reprint Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells
    Doreen Kunze
    Department of Urology, Technical University of Dresden, Fetscherstrasse 74, D 01307 Dresden, Germany
    Anticancer Res 28:2259-63. 2008
    ..The knockdown of XIAP, BCL2 and BCL-X(L) by siRNAs represents a promising treatment option for bladder cancer (BCa) since the overexpression of antiapoptotic genes is often associated with tumor progression and treatment resistance...
  48. doi request reprint Differential expression and action of Toll-like receptors in human adrenocortical cells
    Waldemar Kanczkowski
    Department of Medicine, Carl Gustav Carus University Hospital, Technical University of Dresden, 01307 Dresden, Germany
    Mol Cell Endocrinol 300:57-65. 2009
    ..Therefore, Toll-like receptors expression and function is a novel feature of the adrenal stress system contributing to adrenal tissue homeostasis, regeneration and tumorigenesis...
  49. ncbi request reprint Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo
    Doreen Kunze
    Department of Urology, Faculty of Medicine, Technical University of Dresden, 01307 Dresden, Germany
    Int J Oncol 32:1049-56. 2008
    ..In vivo studies with 9 consecutive intraperitoneal injections with 20 mg/kg AS-ODNs or 4.6 mg/kg siRNAs revealed the biocompatibility of both antisense inhibitor types and showed anti-tumoural activity of the AS-ODNs used...
  50. doi request reprint Interaction between age and comorbidity as predictors of mortality after radical prostatectomy
    Michael Froehner
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    J Urol 179:1823-9; discussion 1829. 2008
    ..We identified an age range in which comorbidity is most closely associated with premature mortality after radical prostatectomy...
  51. doi request reprint Importance of erythrocyte band III anion transporter (SLC4A1) on oxalate clearance of calcium oxalate monohydrate stone-formering patients vs. normal controls
    Sven Oehlschläger
    Department of Urology, Technical University, Dresden, Germany
    Urology 77:250.e1-5. 2011
    ....
  52. doi request reprint Multifocal recurring epithelioid hemangioendothelioma of the penis
    Stefan Zastrow
    Department of Urology, University Hospital Carl Gustav Carus, Dresden, Germany
    Urology 71:351.e9-10. 2008
    ..We present a case of epithelioid hemangioendothelioma of the penis in a 57-year-old man, and its treatment. Differential diagnoses and treatment of this rare disease are discussed...
  53. ncbi request reprint Comorbidity is poor predictor of survival in patients undergoing radical prostatectomy after 70 years of age
    Michael Froehner
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    Urology 68:583-6. 2006
    ....
  54. ncbi request reprint 11C-acetate positron emission tomography for occult prostate cancer
    Michael Froehner
    Department of Urology, University Hospital, Technical University of Dresden, Dresden, Germany
    Urol Oncol 24:410-1. 2006
    ..We report, to our knowledge previously not described, a case of occult prostate cancer, in which 11C-acetate positron emission tomography disclosed tumor manifestation after failure of conventional diagnostic procedures...
  55. ncbi request reprint Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer
    Michael Froehner
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    Urol Int 76:27-30. 2006
    ..To compare the clinical value of the measurement of complex and total PSA in the discrimination between benign prostatic hyperplasia (BPH) and prostate cancer...
  56. ncbi request reprint Comparison of tumor- and comorbidity-related predictors of mortality after radical prostatectomy
    Michael Froehner
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    Scand J Urol Nephrol 39:449-54. 2005
    ..To identify and compare tumor- and non-tumor-related predictors of survival after radical prostatectomy and to incorporate the latter into the tumor node metastasis classification of prostate cancer...
  57. ncbi request reprint Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors
    Panagiotis Tsatalpas
    Department of Urology, University of Dresden, Germany
    Urol Int 68:157-63. 2002
    ..The aim of the present study was to investigate the use of [18F]FDG positron emission tomography ([18F]FDG-PET) in the detection and treatment control of malignant germ cell tumors compared to computed tomography (CT)...
  58. ncbi request reprint Significance of testicular microlithiasis
    Stefan Zastrow
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    Urol Int 75:3-7. 2005
    ..Testicular microlithiasis is an uncommon condition characterized by calcifications within the seminiferous tubules. The true prevalence in a normal population has not been defined...
  59. ncbi request reprint Transcript quantification of Dresden G protein-coupled receptor (D-GPCR) in primary prostate cancer tissue pairs
    Susanne Fuessel
    Department of Urology, Technical University Dresden, Fetscherstr 74, D 01307 Dresden, Germany
    Cancer Lett 236:95-104. 2006
    ..6452. Hence, the evaluation of D-GPCR as possible additive diagnostic tool and putative therapy target appears promising...
  60. ncbi request reprint Renal staghorn calculus?
    Michael Froehner
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    Urology 65:171. 2005
  61. ncbi request reprint Feasibility and limitations of comorbidity measurement in patients undergoing radical prostatectomy
    Michael Froehner
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Fetscherstrasse 74, D 01307 Dresden, Germany
    Eur Urol 47:190-5; discussion 195. 2005
    ..To compare different comorbidity classifications as predictors of survival after radical prostatectomy (RPE)...
  62. ncbi request reprint Urinary immunocytology for primary bladder B cell lymphoma
    Michael Froehner
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    Urology 63:381-3. 2004
    ..Lymphoma cells were distinguished from abundant leukocytes by immunocytologic staining for CD20. This technique might be useful in the differential diagnosis of patients with chronic bladder inflammation accompanied by pyuria...
  63. ncbi request reprint Preoperative cardiopulmonary risk assessment as predictor of early noncancer and overall mortality after radical prostatectomy
    Michael Froehner
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    Urology 61:596-600. 2003
    ..To evaluate the capability of the preoperative cardiopulmonary risk assessment to predict early noncancer and overall mortality after radical prostatectomy for clinically localized prostate cancer...
  64. ncbi request reprint Distal ureteral stenosis after early adjuvant intravesical mitomycin C application for superficial bladder cancer
    Sven Oehlschläger
    Department of Urology, University Hospital Carl Gustav Carus, Technical University Dresden, Germany
    Urol Int 70:74-6. 2003
    ..Although ureteral stenosis does occur after transurethral resection, the severity and time course of the stenosis in this case suggest an influence of the intravesical chemoprophylaxis used...
  65. ncbi request reprint Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor
    Michael Froehner
    Department of Urology, University Hospital, Technical University of Dresden, Fetscherstrasse 74, 01307, Dresden, Germany
    Cancer Chemother Pharmacol 58:716-8. 2006
    ..We report on the--to our knowledge--first treatment experiment with imatinib in a patient with metastatic Leydig cell tumor. Unfortunately, the tumor progressed during treatment...
  66. ncbi request reprint Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA
    Susanne Fuessel
    Department of Urology, Technical University Dresden, Fetscherstr 74, D 01307 Dresden, Germany
    Cancer Lett 232:243-54. 2006
    ..Nevertheless, both therapy approaches in combination with all tested chemotherapeutics provoked a remarkable inhibition of viability and may serve as suitable additive tools for chemosensitization of bladder cancer cells...
  67. ncbi request reprint Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial
    Susanne Fuessel
    Department of Urology, Medical Faculty, Technical University Dresden, Dresden, Germany
    Prostate 66:811-21. 2006
    ....
  68. ncbi request reprint Synthetic nucleic acids as potential therapeutic tools for treatment of bladder carcinoma
    Susanne Fuessel
    Department of Urology, Technical University of Dresden, Dresden, Germany
    Eur Urol 51:315-26; discussion 326-7. 2007
    ..Therefore, silencing of abnormally activated genes appears to be a rational approach for specific target-directed and sensitising therapies...
  69. ncbi request reprint Perioperative complications of radical cystectomy in a contemporary series
    Vladimir Novotny
    Department of Urology, Technical University, Dresden, Germany
    Eur Urol 51:397-401; discussion 401-2. 2007
    ..We retrospectively evaluated our series of patients who underwent radical cystectomy for advanced bladder cancer for perioperative complications as well as operative time, postoperative hospital stay and transfusion rates...
  70. ncbi request reprint New approaches in the modulation of bladder smooth muscle cells on viable detrusor constructs
    Gouya Ram-Liebig
    Department of Urology, Technical University of Dresden, Fetscherstrasse 74, 01307, Dresden, Germany
    World J Urol 24:429-37. 2006
    ..SMC-phenotype can be modulated in viable detrusor constructs by applying selected combinations of urothelial-conditioned media and mechanical stimulation under stepwise reduction and elimination of serum...
  71. ncbi request reprint Impact of resection margin status after nephron-sparing surgery for renal cell carcinoma
    Navid Berdjis
    Department of Urology, University Hospital Carl Gustav Carus, Technical University, Dresden, Germany
    BJU Int 97:1208-10. 2006
    ..To evaluate whether the negative-margin width after nephron-sparing surgery for renal cell carcinoma (RCC) is associated with tumour recurrence...
  72. ncbi request reprint Functional analyses of C13orf19/P38IP in prostate cell lines
    Doreen Kunze
    Department of Urology, Technical University Dresden, Fetscherstrasse 74, D 01307 Dresden, Germany
    Oncol Rep 15:1599-604. 2006
    ..No interaction between C13orf19 and p38MAPK was identified. Therefore, the gene should forthwith be named C13orf19 or Fam48A and not P38IP...
  73. doi request reprint Nomogram underestimates 10-year survival in healthy men selected for radical prostatectomy at age 70 years or older
    Michael Froehner
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    Urology 73:610-3; discussion 613-4. 2009
    ..To externally review a nomogram developed to predict the 10-year survival probability of men selected for radical prostatectomy...
  74. ncbi request reprint Contribution of Ca2+ influx to carbachol-induced detrusor contraction is different in human urinary bladder compared to pig and mouse
    Melinda Wuest
    Department of Pharmacology and Toxicology, Dresden University of Technology, Dresden, Germany
    Eur J Pharmacol 565:180-9. 2007
    ....
  75. pmc Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction
    Melinda Wuest
    Institute of Pharmacology and Toxicology, Dresden University of Technology, Fetscherstrasse 74, D 01307 Dresden, Germany
    Br J Pharmacol 145:608-19. 2005
    ..5. The investigated responses to propiverine and its metabolites suggest that impairment of maximum CCh-induced contractions is due to strong effect on I(Ca) and that this may be associated with the presence of the aliphatic side chain...
  76. ncbi request reprint Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8
    Andrea Kiessling
    Institute of Immunology, Medical Faculty, Technical University of Dresden, Dresden, Germany
    Prostate 56:270-9. 2003
    ..Here, we identify for the first time an immunogenic peptide derived from the prostate-specific protein transient receptor potential-p8 (trp-p8) that is recognized by cytotoxic T lymphocytes (CTLs) from PCa patients...
  77. ncbi request reprint Systematic development of a guideline for early detection of prostate cancer: the German way in the evidence gap
    H J Luboldt
    Department of Urology, University of Duisburg Essen, Hufelandstr 55, Essen, Germany
    Eur Urol 46:725-30. 2004
    ..To develop an evidence-based guideline, helping physcians make prudent decisions about diagnostic care for men wishing to undergo examination for early detection of prostate cancer...
  78. ncbi request reprint [Acute abdominal pain due to a ventriculo-peritoneal shunt metastasis of an intracranial germ cell tumor]
    S Schrodter
    Klinik und Poliklinik fur Urologie, Universitätsklinikum Carl Gustav Carus der technischen Universität Dresden, Fetscherstrasse 74, 01307 Dresden
    Aktuelle Urol 37:141-2. 2006
    ..Extracranial metastases of pineal germinomas are rare...
  79. ncbi request reprint Detection of circulating tumor cells from renal carcinoma patients: experiences of a two-center study
    Karen Blümke
    Clinic of Urology, University Halle Wittenberg, Ernst Grube Str 4, D 06120 Halle Saale, Germany
    Oncol Rep 14:895-9. 2005
    ..The occurrence and the quantity of CTC in RCC patients is an early disease event. Furthermore, the occurrence of CTC is correlated with an advanced tumor stage and seems to be associated with a more aggressive tumor phenotype...
  80. ncbi request reprint Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer
    David G McLeod
    Walter Reed Army Medical Center, Washington, DC, USA
    BJU Int 97:247-54. 2006
    ..To evaluate, in the ongoing Early Prostate Cancer (EPC) trial programme, the efficacy and tolerability of bicalutamide 150 mg once daily in addition to standard care for localized or locally advanced, nonmetastatic prostate cancer...
  81. ncbi request reprint Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program
    William A See
    Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    J Urol 168:429-35. 2002
    ..We determine the efficacy and tolerability of bicalutamide as immediate therapy, either alone or as adjuvant to treatment of curative intent, in patients with clinically localized or locally advanced prostate cancer...
  82. ncbi request reprint Treating renal cell cancer in the elderly
    Navid Berdjis
    Department of Urology, University Hospital Carl Gustav Carus, Technical University Dresden, Fetscherstrasse 74, D 01309 Dresden, Germany
    BJU Int 97:703-5. 2006
    ..To determine whether age and comorbidity are predictors of peri-operative complications and/or mortality in surgery for renal cell cancer in a retrospective study of patients aged >75 years...
  83. ncbi request reprint Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program
    Peter Iversen
    Department of Urology, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark
    Urology 63:928-33. 2004
    ....
  84. ncbi request reprint Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy
    Uta Schmidt
    Technical University of Dresden, Department of Urology, D 01307 Dresden, Germany
    Int J Oncol 24:1393-9. 2004
    ..This study demonstrates that circulating tumor cells are detectable during chemotherapy for hormone-refractory prostate cancer regardless of the degree of PSA response...
  85. ncbi request reprint Chemosensitization of bladder cancer cell lines by human telomerase reverse transcriptase antisense treatment
    Kai Kraemer
    Department of Urology, Technical University Dresden, Dresden, Germany
    J Urol 172:2023-8. 2004
    ..We investigated whether combinations of hTERT antisense (AS)-oligonucleotides (ODNs) with common chemotherapy (CT) schedules may improve drug mediated antitumor effects...
  86. ncbi request reprint Microarray analyses in bladder cancer cells: inhibition of hTERT expression down-regulates EGFR
    Kai Kraemer
    Department of Urology, Technical University of Dresden, Dresden, Germany
    Int J Cancer 119:1276-84. 2006
    ..The detailed clarification of these processes will shed light on the question, whether telomerase inhibitors might constitute suitable anticancer tools...
  87. ncbi request reprint The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use
    Pierre Teillac
    Hopital St Louis, Paris, France
    Clin Ther 27:273-85. 2005
    ..Investigators continue to explore the use of hormone therapy, particularly luteinizing hormone-releasing hormone (LHRH) analogues, earlier in the course of disease...
  88. ncbi request reprint Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme
    Chris J Tyrrell
    Derriford Hospital, Plymouth, UK
    Radiother Oncol 76:4-10. 2005
    ....